Handelsbanken Fonder AB Purchases 60,200 Shares of Roivant Sciences Ltd. $ROIV

Handelsbanken Fonder AB boosted its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 51.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 177,209 shares of the company’s stock after acquiring an additional 60,200 shares during the period. Handelsbanken Fonder AB’s holdings in Roivant Sciences were worth $6,271,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Pictet Asset Management Holding SA grew its holdings in shares of Roivant Sciences by 790.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock valued at $50,180,000 after buying an additional 2,052,693 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Roivant Sciences by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after purchasing an additional 3,254,113 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its stake in shares of Roivant Sciences by 90.9% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 80,561 shares of the company’s stock worth $1,746,000 after purchasing an additional 38,354 shares during the last quarter. Nicholas Investment Partners LP lifted its holdings in shares of Roivant Sciences by 13.9% in the fourth quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company’s stock valued at $6,073,000 after purchasing an additional 34,235 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in shares of Roivant Sciences in the fourth quarter valued at approximately $76,272,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

ROIV has been the subject of several recent research reports. Citigroup upped their price target on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a report on Monday. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Thursday, August 6th. Guggenheim upped their price objective on shares of Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Weiss Ratings cut shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $35.14.

Insider Buying and Selling

In other news, Director Melissa B. Epperly sold 17,750 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $34.38, for a total transaction of $610,245.00. Following the transaction, the director owned 16,474 shares of the company’s stock, valued at $566,376.12. This represents a 51.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total value of $436,766.40. Following the completion of the sale, the director directly owned 13,689,166 shares of the company’s stock, valued at approximately $482,953,776.48. This trade represents a 0.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 2,055,913 shares of company stock valued at $69,639,633. 8.80% of the stock is owned by company insiders.

Roivant Sciences Stock Performance

NASDAQ ROIV opened at $36.20 on Friday. The company has a market capitalization of $26.04 billion, a PE ratio of -68.30 and a beta of 1.12. Roivant Sciences Ltd. has a 52-week low of $11.54 and a 52-week high of $37.00. The company has a 50-day simple moving average of $33.84 and a 200 day simple moving average of $29.91.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.